
  
    
      
        Background_NNP
        Lung_NNP cancer_NN is_VBZ the_DT leading_VBG killer_NN of_IN all_DT cancer_NN
        patients_NNS ._. It_PRP is_VBZ generally_RB classified_VBN as_IN small_JJ cell_NN
        carcinoma_NN and_CC non-small_JJ cell_NN carcinoma_NN ._. Treatment_NNP of_IN lung_NN
        cancer_NN is_VBZ less_JJR than_IN optimal_NN and_CC the_DT mean_JJ survival_NN for_IN
        advanced_JJ lung_NN cancer_NN patient_NN is_VBZ less_JJR than_IN one_CD year_NN
        regardless_RB what_WP treatment_NN regimen_NN was_VBD used_VBN [_NN 1_CD ]_NN ._. A_DT new_JJ
        approach_NN other_JJ than_IN conventional_JJ chemoradiation_NN therapy_NN is_VBZ
        needed_VBN for_IN prolonged_JJ survival_NN of_IN lung_NN cancer_NN ._. Emerging_VBG new_JJ
        treatment_NN modalities_NNS are_VBP generally_RB targeted_VBN to_TO specific_JJ
        tyrosine_NN kinases_NNS of_IN the_DT tumor_NN cells_NNS through_IN basically_RB two_CD
        independent_JJ approaches_NNS [_NN 2_CD ]_NN ._. One_CD is_VBZ to_TO use_VB highly_RB
        specific_JJ monoclonal_NN antibody_NN to_TO target_VB the_DT membrane_NN
        receptors_NNS of_IN growth_NN factors_NNS important_JJ for_IN tumor_NN cell_NN
        growth_NN ,_, and_CC the_DT antibody_NN /_NN antigen_NN complex_JJ evokes_VBZ host_NN immune_JJ
        system_NN to_TO kill_VB the_DT tumor_NN cells_NNS ._. This_DT approach_NN is_VBZ
        exemplified_VBN by_IN Her_PRP$ 2_CD /_NN neu_NN receptor_NN in_IN breast_NN cancer_NN patients_NNS
        and_CC Herceptin_NNP [_NN 3_CD ]_NN ._. The_DT second_JJ approach_NN is_VBZ to_TO develop_VB
        small_JJ organic_JJ molecules_NNS targeting_VBG the_DT specific_JJ tyrosine_NN
        kinases_NNS in_IN the_DT signaling_VBG pathway_NN in_IN the_DT tumor_NN cells_NNS that_WDT
        can_MD easily_RB gain_VB access_NN into_IN the_DT tumor_NN cells_NNS ._. This_DT approach_NN
        is_VBZ best_RBS exemplified_VBN by_IN Gleevec_NNP and_CC BCR-ABL_NNP fusion_NN kinase_NN in_IN
        chronic_JJ myelogenous_JJ leukemia_NN [_NN 4_CD ]_NN ._.
        Gleevec_NNP (_( also_RB known_VBN as_IN STI_NNP 571_CD ,_, Imatinib_NNP from_IN Novartis_NNP
        Pharmaceutical_NNP Inc_NNP ._. )_) ,_, a_DT recently_RB FDA_NNP approved_VBD drug_NN for_IN
        chronic_JJ myelogenous_JJ leukemia_NN ,_, is_VBZ an_DT ATP_NNP analogue_NN ,_, and_CC it_PRP
        competitively_RB binds_NNS to_TO and_CC inhibits_NNS BCR-ABL_NNP tyrosine_NN
        kinase_NN ,_, resulted_VBD from_IN the_DT chromosomal_NN translocation_NN t_NN (_( 9_CD ;_:
        22_CD )_) ._. Gleevec_NNP has_VBZ been_VBN shown_VBN to_TO induce_VB clinical_JJ ,_,
        hematological_JJ and_CC molecular_JJ remissions_NNS for_IN CML_NNP patients_NNS [_NN 4_CD
        ]_NN ._. It_PRP cross-reacts_JJ with_IN two_CD other_JJ important_JJ growth_NN factor_NN
        receptors_NNS containing_VBG tyrosine_NN kinase_NN domains_NNS ,_, c-kit_JJ and_CC
        PDGF_NNP receptors_NNS ,_, that_WDT play_VBP important_JJ roles_NNS in_IN growth_NN and_CC
        proliferation_NN of_IN a_DT variety_NN of_IN cell_NN types_NNS [_NN 5_CD ]_NN ._. C-_NNP kit_NN
        (_( also_RB known_VBN as_IN CD_NNP 117_CD )_) is_VBZ frequently_RB mutated_VBN in_IN
        gastrointestinal_NN stromal_NN tumor_NN (_( GIST_NNP )_) ,_, and_CC the_DT mutated_VBN
        c-kit_JJ shows_VBZ higher_JJR tyrosine_NN kinase_NN activity_NN ._. Gleevec_NNP has_VBZ
        been_VBN demonstrated_VBN to_TO inhibit_VB the_DT growth_NN and_CC proliferation_NN
        of_IN GIST_NNP ,_, and_CC induce_VB complete_JJ or_CC partial_JJ clinical_JJ remission_NN
        in_IN GIST_NNP patients_NNS [_NN 6_CD 7_CD ]_NN ._. Recently_RB Gleevec_NNP was_VBD showed_VBN to_TO
        inhibit_VB the_DT growth_NN of_IN dermatofibrosarcma_NN protuberans_NNS (_( DFSP_NNP )_)
        through_IN inhibiting_VBG the_DT PDGF_NNP receptor_NN [_NN 8_CD 9_CD ]_NN ._.
        As_IN a_DT part_NN of_IN effort_NN to_TO evaluate_VB the_DT newly_RB emerging_VBG drugs_NNS
        for_IN lung_NN cancer_NN ,_, we_PRP studied_VBD the_DT role_NN of_IN Gleevec_NNP on_IN
        non-small_JJ cell_NN lung_NN cancer_NN ._. We_PRP previously_RB showed_VBD that_IN
        non-small_JJ cell_NN lung_NN cancers_NNS express_VBP minimal_JJ (_( negligible_JJ )_)
        level_NN of_IN c-kit_JJ (_( Zhang_NNP ,_, P_NN ._. ,_, unpublished_JJ )_) ._. Therefore_RB it_PRP is_VBZ
        unlikely_JJ that_IN Gleevec_NNP exerts_NNS the_DT effect_NN ,_, if_IN any_DT ,_, through_IN
        c-kit_JJ on_IN non-small_JJ cell_NN lung_NN cancer_NN ._. We_PRP reported_VBD here_RB a_DT
        study_NN of_IN inhibitory_NN effect_NN of_IN Gleevec_NNP on_IN lung_NN cancer_NN cells_NNS
        (_( A_DT 549_CD cells_NNS )_) in_IN vitro_NN ._. We_PRP showed_VBD that_IN Gleevec_NNP alone_RB can_MD
        inhibit_VB the_DT growth_NN and_CC proliferation_NN of_IN A_DT 549_CD cells_NNS at_IN the_DT
        known_VBN therapeutic_JJ concentration_NN for_IN CML_NNP ._. Addition_NNP of_IN
        Gleevec_NNP to_TO A_DT 549_CD cells_NNS with_IN cisplatin_NN induced_VBD cell_NN death_NN
        synergistically_RB ,_, suggesting_VBG Gleevec_NNP can_MD potentiate_NN the_DT
        cisplatin_NN effect_NN on_IN A_DT 549_CD cells_NNS ._. We_PRP have_VBP demonstrated_VBN that_IN
        A_DT 549_CD cells_NNS express_VBP PDGFR_NNP α_NN ,_, one_CD of_IN the_DT known_VBN potential_JJ
        targets_NNS for_IN Gleevec_NNP effect_NN ._. The_DT inhibitory_NN effect_NN of_IN
        Gleevec_NNP on_IN the_DT A_DT 549_CD cells_NNS is_VBZ likely_JJ mediated_JJ through_IN
        inhibition_NN of_IN PDGF_NNP receptor_NN α_NN phosphorylation_NN ._. We_PRP further_RBR
        tested_VBN 33_CD lung_NN cancer_NN patients_NNS '_POS tumor_NN specimens_NNS ,_, and_CC showed_VBD
        that_IN most_JJS of_IN the_DT lung_NN cancer_NN tumor_NN specimens_NNS expressed_VBD
        PDGFR-α_NNP ._. These_DT results_NNS provided_VBD important_JJ in_IN vitro_NN data_NNS to_TO
        support_VB the_DT notion_NN that_IN Gleevec_NNP can_MD inhibit_VB the_DT A_DT 549_CD cell_NN
        growth_NN and_CC proliferation_NN ,_, and_CC may_MD potentially_RB offer_VB a_DT
        treatment_NN option_NN for_IN lung_NN cancer_NN either_CC alone_RB or_CC in_IN
        conjunction_NN with_IN chemotherapy_NN drug_NN cisplatin_NN ._.
      
      
        Results_NNS
        
          Gleevec_NNP inhibited_VBD the_DT A_DT 549_CD cell_NN growth_NN in_IN a_DT
          dose-dependent_JJ manner_NN
          We_PRP first_JJ test_NN to_TO see_VB if_IN Gleevec_NNP can_MD inhibit_VB the_DT growth_NN
          of_IN A_DT 549_CD cells_NNS under_IN the_DT culture_NN conditions_NNS ._. We_PRP have_VBP
          chosen_VBN to_TO perform_VB the_DT experiments_NNS under_IN the_DT normal_JJ
          culture_NN condition_NN since_IN we_PRP reasoned_VBD that_IN the_DT effect_NN of_IN
          Gleevec_NNP on_IN tumor_NN cells_NNS ,_, if_IN any_DT ,_, should_MD be_VB under_IN the_DT
          normal_JJ ,_, not_RB serum_NN free_JJ condition_NN ._. Therefore_RB ,_, we_PRP chose_VBD to_TO
          add_VB the_DT drug_NN directly_RB into_IN the_DT culture_NN medium_NN containing_VBG
          5_CD %_NN fetal_JJ calf_NN serum_NN ._. A_DT 549_CD lung_NN cancer_NN cells_NNS were_VBD plated_JJ
          at_IN two_CD cell_NN densities_NNS into_IN the_DT 96_CD well_RB plates_NNS ,_, and_CC
          Gleevec_NNP was_VBD added_VBN to_TO the_DT culture_NN medium_NN ._. We_PRP used_VBD the_DT MTT_NNP
          assays_NNS to_TO assess_VB the_DT viability_NN of_IN the_DT tumor_NN cells_NNS treated_VBN
          with_IN or_CC without_IN the_DT drug_NN ._. It_PRP was_VBD evident_JJ that_IN increasing_VBG
          concentrations_NNS of_IN Gleevec_NNP in_IN the_DT culture_NN medium_NN inhibited_VBD
          the_DT growth_NN of_IN A_DT 549_CD cells_NNS in_IN a_DT dose_NN dependent_JJ manner_NN ._. The_DT
          concentration_NN of_IN Gleevec_NNP to_TO inhibit_VB 50_CD %_NN cell_NN growth_NN
          (_( IC_NNP 50_CD )_) was_VBD estimated_VBN to_TO be_VB around_IN 2_CD -_: 3_CD μM_NN (_( Figure_NN 1_LS )_) ,_,
          whereas_IN the_DT IC_NNP 50_CD of_IN cisplatin_NN on_IN A_DT 549_CD cells_NNS was_VBD estimated_VBN
          to_TO be_VB 64_CD -_: 70_CD μM_NN (_( Figure_NN 2_LS )_) ._. We_PRP have_VBP also_RB seen_VBN that_IN Gleevec_NNP
          can_MD inhibit_VB the_DT growth_NN of_IN human_JJ 293_CD kidney_NN cells_NNS ,_, but_CC at_IN
          slightly_RB higher_JJR concentration_NN (_( 4_CD μM_NN )_) ._. The_DT IC_NNP 50_CD
          concentration_NN for_IN A_DT 549_CD cells_NNS did_VBD n't_RB appear_VB to_TO have_VB
          inhibitory_NN effects_NNS on_IN human_JJ 293_CD cells_NNS (_( Figure_NN 3_LS )_) ._. These_DT
          results_NNS showed_VBD that_IN Gleevec_NNP alone_RB can_MD indeed_RB inhibit_VB the_DT
          growth_NN of_IN A_DT 549_CD lung_NN carcinoma_NN cells_NNS ._. The_DT inhibitory_NN
          effect_NN of_IN Gleevec_NNP on_IN the_DT A_DT 549_CD cells_NNS appeared_VBD to_TO be_VB in_IN a_DT
          therapeutic_JJ range_NN of_IN the_DT drug_NN as_IN demonstrated_VBN in_IN chronic_JJ
          myelogenous_JJ leukemia_NN cells_NNS from_IN the_DT patients_NNS ._.
        
        
          Gleevec_NNP potentiated_JJ the_DT cell-killing_JJ effect_NN of_IN
          cisplatin_NN
          One_CD of_IN the_DT major_JJ reasons_NNS of_IN testing_NN Gleevec_NNP for_IN
          treatment_NN of_IN non-small_JJ cell_NN lung_NN carcinoma_NN is_VBZ to_TO see_VB if_IN
          the_DT specific_JJ tyrosine_NN kinase_NN inhibitor_NN Gleevec_NNP ,_, and_CC other_JJ
          potential_JJ small_JJ molecules_NNS currently_RB on_IN clinical_JJ trials_NNS ,_,
          can_MD be_VB used_VBN as_IN an_DT adjuvant_NN therapeutic_JJ agent_NN in_IN
          combination_NN with_IN conventional_JJ chemotherapy_NN ._. We_PRP sought_VBD to_TO
          see_VB if_IN Gleevec_NNP can_MD potentiate_NN the_DT cell_NN killing_VBG effects_NNS of_IN
          cisplatin_NN ,_, the_DT leading_VBG chemotherapeutic_JJ drug_NN for_IN almost_RB
          all_DT advanced_VBN cancer_NN patients_NNS ._. We_PRP used_VBD the_DT IC_NNP 50_CD
          concentrations_NNS for_IN both_DT Gleevec_NNP and_CC cisplatin_NN to_TO treat_VB
          A_DT 549_CD cells_NNS in_IN culture_NN ,_, and_CC assessed_VBD the_DT viability_NN of_IN the_DT
          cells_NNS by_IN MTT_NNP assays_NNS at_IN the_DT different_JJ time_NN points_NNS (_( Figure_NN
          4_LS )_) ._. Gleevec_NNP (_( 2_CD μM_NN )_) and_CC cisplatin_NN (_( 64_CD μM_NN )_) both_DT inhibited_VBD
          the_DT growth_NN of_IN the_DT tumor_NN cells_NNS individually_RB after_IN
          treatment_NN of_IN the_DT cells_NNS for_IN 48_CD hour_NN ._. Combination_NNP of_IN
          Gleevec_NNP and_CC cisplatin_NN synergistically_RB inhibited_VBD the_DT
          growth_NN of_IN A_DT 549_CD cells_NNS (_( Figure_NN 4_LS )_) ._. This_DT synergistic_JJ effect_NN
          of_IN Gleevec_NNP and_CC cisplatin_NN on_IN A_DT 549_CD lung_NN cancer_NN cells_NNS were_VBD
          not_RB seen_VBN for_IN human_JJ 293_CD kidney_NN cells_NNS (_( Figure_NN 5_LS )_) ._.
        
        
          Expression_NNP of_IN PDGFR-α_NNP in_IN the_DT A_DT 549_CD lung_NN cancer_NN
          cells_NNS
          Since_IN the_DT effect_NN of_IN Gleevec_NNP is_VBZ mediated_JJ through_IN
          inhibiting_VBG BCR-ABL_NNP tyrosine_NN kinase_NN ,_, c-kit_JJ ,_, and_CC PDGF_NNP
          receptors_NNS ,_, we_PRP are_VBP interested_JJ in_IN the_DT potential_JJ target_NN for_IN
          Gleevec_NNP effect_NN in_IN the_DT lung_NN cancer_NN cells_NNS ._. We_PRP have_VBP
          previously_RB showed_VBN by_IN immunohistochemical_JJ staining_VBG that_IN in_IN
          54_CD primary_JJ non-small_JJ cell_NN lung_NN carcinoma_NN specimens_NNS ,_,
          expression_NN of_IN c-kit_JJ was_VBD weak_JJ and_CC minimal_JJ ,_, if_IN any_DT (_( Tang_NNP
          and_CC Zhang_NNP ,_, unpublished_JJ observation_NN )_) ._. We_PRP sought_VBD to_TO
          determine_VB the_DT expression_NN levels_NNS of_IN PDGF_NNP receptors_NNS α_NN and_CC β_NN
          in_IN A_DT 549_CD cells_NNS and_CC the_DT primary_JJ non-small_JJ cell_NN lung_NN
          carcinoma_NN by_IN immunofluorescent_NN and_CC immunohistochemical_JJ
          staining_VBG methods_NNS ._. In_IN A_DT 549_CD cells_NNS ,_, expression_NN of_IN PDGFR-α_NNP ,_,
          not_RB PDGFR-β_NNP ,_, was_VBD detected_VBN with_IN strong_JJ cytoplasmic_JJ and_CC
          membrane_NN staining_VBG patterns_NNS (_( Figure_NN 6_CD and_CC 7_CD )_) ._. There_EX was_VBD no_DT
          demonstrable_JJ nuclear_JJ staining_VBG signal_NN ._. We_PRP further_RBR detected_VBD
          the_DT presence_NN of_IN PDGFR-α_NNP in_IN the_DT whole_JJ cell_NN lysates_NNS of_IN A_DT 549_CD
          cells_NNS by_IN Western_NNP blotting_VBG analysis_NN (_( Figure_NN 8_CD )_) ._. A_DT 549_CD cells_NNS
          were_VBD cultured_JJ under_IN the_DT condition_NN described_VBD ,_, and_CC the_DT
          cells_NNS were_VBD lysed_JJ and_CC the_DT whole_JJ cell_NN proteins_NNS were_VBD
          separated_JJ on_IN 7_CD ._. 5_CD %_NN SDS-PAGE_NNP ._. The_DT proteins_NNS were_VBD transferred_VBN
          onto_IN nitrocellulose_NN membrane_NN ,_, and_CC the_DT PDGFR-α_NNP was_VBD
          detected_VBN with_IN anti-_NN PDGFR-α_NNP antibody_NN (_( Santa_NNP Cruz_NNP
          Biotechnologies_NNP Inc_NNP ._. )_) ._. Treatment_NNP of_IN the_DT cells_NNS with_IN
          Gleevec_NNP at_IN two_CD concentrations_NNS did_VBD not_RB influence_VB the_DT
          expression_NN of_IN PDGFR-α_NNP expression_NN in_IN the_DT cells_NNS ._. PDGFR-β_NNP
          was_VBD not_RB detected_VBN in_IN A_DT 549_CD cells_NNS using_VBG both_DT
          immunofluorescent_NN staining_VBG and_CC Western_JJ blot_NN analyses_NNS
          (_( Data_NNP not_RB shown_VBN )_) ._.
        
        
          Microarrays_NNP and_CC immunohistochemical_JJ staining_VBG
          Existing_JJ data_NNS suggest_VBP that_IN Gleevec_NNP can_MD exert_VB its_PRP$
          inhibitory_NN effect_NN on_IN tumor_NN cells_NNS through_IN inhibiting_VBG PDGF_NNP
          receptor_NN function_NN ,_, and_CC we_PRP have_VBP shown_VBN that_IN the_DT primary_JJ
          non-small_JJ cells_NNS lung_NN cancer_NN expressed_VBD minimal_JJ c-_NN Kit_NNP ._. We_PRP
          would_MD like_VB to_TO see_VB if_IN PDGF_NNP receptor_NN expression_NN in_IN lung_NN
          cancer_NN patients_NNS is_VBZ frequent_JJ finding_NN ,_, and_CC this_DT could_MD
          potentially_RB provide_VB a_DT cellular_JJ mechanism_NN by_IN which_WDT Gleevec_NNP
          inhibits_NNS the_DT lung_NN cancer_NN tumor_NN growth_NN ._. We_PRP used_VBD the_DT tumor_NN
          tissue_NN micro-array_JJ technique_NN using_VBG the_DT high-density_JJ lung_NN
          tissue_NN arrays_NNS from_IN Clinomic_NNP Biosciences_NNP Inc_NNP ,_, MA_NNP ._. Lung_NNP
          tissue_NN micro-array_JJ slides_NNS containing_VBG 33_CD primary_JJ lung_NN
          cancer_NN tumor_NN specimens_NNS with_IN the_DT corresponding_JJ normal_JJ lung_NN
          tissues_NNS were_VBD used_VBN for_IN immunohistochemical_JJ staining_VBG using_VBG
          anti-_NN PDGFR-α_NNP and_CC β_NN antibodies_NNS as_IN described_VBN ._. The_DT clinical_JJ
          diagnoses_NNS of_IN lung_NN cancers_NNS were_VBD reviewed_VBN and_CC confirmed_VBN ._.
          Using_VBG clinical_JJ diagnostic_JJ criteria_NNS ,_, the_DT immunostaining_VBG
          patterns_NNS and_CC intensities_NNS were_VBD verified_VBN by_IN two_CD independent_JJ
          board_NN certified_VBN surgical_JJ pathologists_NNS ._. Since_IN
          immunohistochemical_JJ staining_VBG is_VBZ a_DT semi-quantitative_JJ
          method_NN ,_, we_PRP scored_VBD the_DT staining_VBG intensities_NNS arbitrarily_RB as_IN
          1_CD +_NN ,_, 2_CD +_NN and_CC 3_CD +_NN (_( Figure_NN 9_CD )_) ._. There_EX were_VBD 18_CD cases_NNS of_IN squamous_JJ
          carcinomas_NNS of_IN the_DT lung_NN within_IN the_DT tissue_NN array_NN slide_NN ,_, and_CC
          16_CD of_IN the_DT 18_CD cases_NNS were_VBD positive_JJ for_IN PDGFR-α_NNP (_( 89_CD %_NN )_) ._. 7_CD of_IN
          the_DT 16_CD cases_NNS were_VBD scored_VBN 1_CD +_NN (_( 39_CD %_NN )_) ,_, 5_CD cases_NNS 2_CD +_NN (_( 28_CD %_NN )_) and_CC 4_CD
          cases_NNS 3_CD +_NN positivity_NN (_( 22_CD %_NN )_) (_( Table_NNP 1_LS )_) ._. There_EX were_VBD 11_CD of_IN the_DT
          11_CD adenocarcinoma_NN specimens_NNS that_WDT were_VBD positive_JJ for_IN
          PDGFR-α_NNP (_( 100_CD %_NN )_) [_NN 6_CD cases_NNS 1_CD +_NN (_( 55_CD %_NN )_) ,_, 3_CD cases_NNS 2_CD +_NN (_( 27_CD %_NN )_) ,_, 2_CD
          cases_NNS 3_CD +_NN (_( 18_CD %_NN )_) respectively_RB ]_NN ._. Small_JJ cell_NN carcinomas_NNS were_VBD
          also_RB positive_JJ expression_NN of_IN PDGFR-α_NNP [_NN 4_CD cases_NNS 2_CD +_NN (_( 100_CD %_NN )_) ]_NN ._.
          Two_CD cases_NNS of_IN malignant_JJ mesotheliomas_NNS were_VBD negative_JJ for_IN
          PDGFR-α_NNP ._. The_DT corresponding_JJ normal_JJ lung_NN tissues_NNS were_VBD found_VBN
          to_TO be_VB negative_JJ for_IN PDGFR-α_NNP ._. Although_IN there_EX were_VBD some_DT
          interstitial_NN staining_VBG signals_NNS for_IN PDGFR-β_NNP ,_, the_DT tumor_NN
          tissues_NNS were_VBD negative_JJ for_IN PDGFR-β_NNP (_( Figure_NN 7_CD ,_, micro-array_JJ
          data_NNS not_RB shown_VBN )_) ._. These_DT results_NNS demonstrated_VBN that_IN PDGFR-α_NNP
          expression_NN is_VBZ elevated_VBD in_IN the_DT tumor_NN tissues_NNS compared_VBN to_TO
          normal_JJ lung_NN parenchyma_NN ,_, and_CC the_DT expression_NN of_IN PDGFR-α_NNP in_IN
          tumor_NN tissue_NN may_MD play_VB important_JJ roles_NNS in_IN tumor_NN growth_NN and_CC
          progression_NN ._.
        
      
      
        Discussion_NNP
        
          Gleevec_NNP effects_VBZ vs_NNS drug_NN toxicity_NN
          We_PRP have_VBP shown_VBN in_IN this_DT study_NN that_IN Gleevec_NNP alone_RB can_MD
          inhibit_VB the_DT growth_NN of_IN A_DT 549_CD cells_NNS at_IN the_DT concentration_NN of_IN
          2_CD -_: 3_CD μM_NN (_( IC_NNP 50_CD )_) ._. This_DT is_VBZ within_IN the_DT known_VBN therapeutic_JJ
          ranges_NNS for_IN patients_NNS with_IN CML_NNP ,_, since_IN the_DT plasma_NN levels_NNS of_IN
          Gleevec_NNP inducing_VBG hematologic_JJ and_CC cytogenetic_JJ response_NN in_IN
          patients_NNS with_IN CML_NNP were_VBD reported_VBN to_TO be_VB in_IN the_DT range_NN of_IN
          0_CD ._. 1_CD -_: 3_CD ._. 4_LS μg_NN /_NN ml_NN (_( 0_CD ._. 17_CD -_: 5_CD ._. 68_CD μM_NN )_) after_IN treatment_NN with_IN 25_CD -_: 600_CD
          mg_NN /_NN day_NN [_NN 4_CD ]_NN ._. In_IN our_PRP$ system_NN ,_, the_DT level_NN of_IN Gleevec_NNP at_IN
          the_DT tested_VBN concentration_NN was_VBD in_IN the_DT low_JJ micromolar_NN
          ranges_NNS ,_, and_CC the_DT inhibitory_NN effect_NN of_IN Gleevec_NNP on_IN A_DT 549_CD
          cells_NNS is_VBZ likely_JJ to_TO be_VB genuine_JJ through_IN binding_VBG to_TO the_DT
          receptor_NN ,_, not_RB due_JJ to_TO the_DT toxic_JJ effects_NNS of_IN the_DT drug_NN ._. This_DT
          inhibitory_NN effect_NN can_MD also_RB be_VB seen_VBN with_IN the_DT human_JJ kidney_NN
          293_CD cells_NNS with_IN slight_JJ higher_JJR IC_NNP 50_CD ._. At_IN the_DT concentration_NN
          of_IN 4_CD μM_NN or_CC higher_JJR ,_, the_DT inhibitory_NN effect_NN of_IN Gleevec_NNP on_IN
          both_DT A_DT 549_CD and_CC 293_CD cells_NNS were_VBD found_VBN to_TO be_VB identical_JJ
          (_( Figure_NN 2_CD and_CC 3_LS )_) ._. Higher_JJR concentration_NN than_IN 6_CD μM_NN in_IN the_DT
          cell_NN culture_NN condition_NN is_VBZ unlikely_JJ to_TO be_VB translated_VBN to_TO
          clinical_JJ patients_NNS ,_, since_IN the_DT adverse_JJ effects_NNS of_IN the_DT drug_NN
          will_MD become_VB intolerable_JJ for_IN the_DT patients_NNS ._.
        
        
          Potential_JJ target_NN of_IN Gleevec_NNP in_IN lung_NN cancers_NNS
          Gleevec_NNP was_VBD designed_VBN to_TO inhibit_VB the_DT BCR-ABL_NNP tyrosine_NN
          kinase_NN ,_, and_CC it_PRP cross-reacts_JJ with_IN c-kit_JJ and_CC PDGFR_NNP [_NN 5_CD ]_NN ._.
          In_IN non-small_JJ cell_NN lung_NN cancer_NN ,_, BCR-ABL_NNP expression_NN has_VBZ
          never_RB been_VBN reported_VBN ,_, and_CC it_PRP is_VBZ unlikely_JJ that_IN BCR-ABL_NNP
          fusion_NN protein_NN plays_VBZ any_DT role_NN in_IN lung_NN cancer_NN ._. There_EX has_VBZ
          been_VBN no_DT report_NN to_TO link_VB cellular_JJ ABL_NNP kinase_NN mutation_NN to_TO
          any_DT cancer_NN patients_NNS except_IN BCR-ABL_NNP in_IN CML_NNP ,_, although_IN the_DT
          detailed_VBN c-_NN Abl_NNP function_NN has_VBZ not_RB been_VBN extensively_RB studied_VBN
          in_IN lung_NN cancer_NN patients_NNS ._. CAbl_NNP is_VBZ a_DT tyrosine_NN kinase_NN that_WDT
          plays_VBZ important_JJ roles_NNS in_IN cell_NN growth_NN ,_, differentiation_NN and_CC
          apoptosis_NNS ._. Although_IN c-_NN Abl_NNP mutations_NNS have_VBP not_RB been_VBN
          reported_VBN in_IN human_JJ cancers_NNS ,_, c-_NN Abl_NNP related_VBD protein_NN ,_, ARG_NNP (_( or_CC
          Abl-_NNP 2_LS )_) ,_, was_VBD shown_VBN to_TO be_VB regulated_VBN in_IN non-small_JJ cell_NN lung_NN
          cancers_NNS by_IN hypermethylation_NN (_( Dr_NNP ._. Steven_NNP Reynolds_NNP ,_,
          National_NNP Institute_NNP of_IN Occupational_NNP and_CC Safety_NNP Health_NNP ,_,
          Morgantown_NNP ,_, WV_NNP ,_, personal_JJ communication_NN )_) ._. ARG_NNP shares_NNS
          significant_JJ homology_NN with_IN c-_NN Abl_NNP throughout_IN the_DT amino_JJ acid_NN
          sequences_NNS ._. Gleevec_NNP has_VBZ been_VBN shown_VBN to_TO inhibit_VB ARG_NNP tyrosine_NN
          kinase_NN [_NN 10_CD ]_NN (_( Dr_NNP ._. Jean_NNP Wang_NNP ,_, Biology_NNP ,_, University_NNP of_IN
          California_NNP San_NNP Diego_NNP ,_, personal_JJ communication_NN )_) ,_, although_IN
          the_DT functional_JJ significance_NN of_IN ARG_NNP kinase_NN in_IN lung_NN cancer_NN
          is_VBZ yet_RB to_TO be_VB elucidated_JJ ._.
          We_PRP have_VBP studied_VBN the_DT expression_NN of_IN c-kit_JJ (_( CD_NNP 117_CD )_) in_IN the_DT
          non-small_JJ cell_NN lung_NN cancer_NN patients_NNS ,_, and_CC we_PRP found_VBD that_IN
          approximately_RB 13_CD %_NN of_IN the_DT tumor_NN specimens_NNS were_VBD weakly_RB
          positive_JJ for_IN c-kit_JJ ._. The_DT level_NN of_IN expression_NN is_VBZ generally_RB
          weak_JJ (_( 1_CD +_NN )_) ._. These_DT results_NNS lead_VBP us_PRP to_TO find_VB an_DT alternative_JJ
          target_NN for_IN Gleevec_NNP ,_, because_IN of_IN the_DT low_JJ expression_NN level_NN
          and_CC low_JJ frequency_NN of_IN expression_NN of_IN c-kit_JJ in_IN the_DT lung_NN
          cancer_NN patients_NNS ._.
        
        
          PDGFR_NNP expression_NN in_IN lung_NN cancer_NN
          We_PRP have_VBP shown_VBN convincingly_RB that_DT lung_NN cancer_NN cell_NN A_DT 549_CD
          expressed_VBD PDGFR-α_NNP both_DT by_IN immunostaining_VBG the_DT cells_NNS and_CC by_IN
          Western_JJ blot_NN analysis_NN ._. PDGF_NNP receptors_NNS are_VBP widely_RB
          expressed_VBN in_IN a_DT variety_NN of_IN tissues_NNS ,_, and_CC the_DT levels_NNS of_IN
          expression_NN in_IN normal_JJ tissues_NNS are_VBP minimal_JJ ._. Over-expression_NNP
          of_IN PDGFR_NNP has_VBZ been_VBN reported_VBN in_IN a_DT variety_NN of_IN human_JJ tumors_NNS
          including_VBG glioma_NN and_CC glioblastoma_NN ,_, pancreatic_JJ and_CC colonic_JJ
          cancers_NNS ,_, breast_NN ,_, bone_NN and_CC ovarian_NN tumors_NNS [_NN 11_CD ]_NN ._. In_IN
          normal_JJ cells_NNS ,_, expression_NN of_IN PDGFR_NNP can_MD be_VB seen_VBN in_IN the_DT
          fibroblasts_NNS and_CC the_DT smooth_JJ muscle_NN cells_NNS in_IN the_DT lung_NN and_CC
          airway_NN [_NN 12_CD ]_NN ._. There_EX is_VBZ so_RB far_RB to_TO our_PRP$ knowledge_NN no_DT
          report_NN to_TO link_VB the_DT expression_NN of_IN PDGFR_NNP to_TO lung_NN cancer_NN ._.
          Since_IN it_PRP has_VBZ been_VBN reported_VBN that_IN Gleevec_NNP can_MD inhibit_VB the_DT
          function_NN of_IN PDGFR_NNP under_IN the_DT cell_NN culture_NN conditions_NNS ,_, it_PRP
          is_VBZ likely_JJ that_IN Gleevec_NNP exerts_NNS its_PRP$ inhibitory_NN effects_NNS on_IN
          A_DT 549_CD lung_NN cancer_NN cells_NNS through_IN inhibiting_VBG the_DT PDGFR_NNP
          function_NN ._.
        
        
          Synergistic_NNP effect_NN of_IN Gleevec_NNP and_CC cisplatin_NN on_IN A_DT 549_CD
          cells_NNS
          We_PRP have_VBP shown_VBN that_IN Gleevec_NNP can_MD exert_VB its_PRP$ effect_NN
          synergistically_RB with_IN cisplatin_NN ._. Cisplatin_NNP causes_VBZ two_CD
          types_NNS of_IN DNA_NNP damage_NN ,_, DNA_NNP adducts_NNS and_CC inter-stranded_JJ
          cross-linking_JJ ,_, resulting_VBG in_IN activation_NN of_IN apoptosis_NNS
          pathway_NN in_IN the_DT target_NN tumor_NN cells_NNS [_NN 13_CD 14_CD ]_NN ._. Our_PRP$ results_NNS
          suggest_VBP that_DT inhibition_NN of_IN tyrosine_NN kinase_NN activity_NN of_IN
          the_DT potential_JJ targets_NNS by_IN Gleevec_NNP appear_VBP to_TO potentiate_NN the_DT
          effect_NN of_IN cisplatin_NN in_IN DNA-damage_NNP induced_VBD apoptosis_NNS in_IN
          A_DT 549_CD cells_NNS ._. Although_IN the_DT underlying_VBG mechanism_NN of_IN such_JJ
          synergism_NN is_VBZ unclear_JJ ,_, it_PRP is_VBZ of_IN great_JJ interest_NN to_TO combine_VB
          the_DT two_CD drugs_NNS in_IN clinical_JJ lung_NN cancer_NN patients_NNS to_TO see_VB if_IN
          the_DT synergy_NN of_IN the_DT two_CD drugs_NNS exists_VBZ under_IN the_DT
          physiological_JJ conditions_NNS ._. It_PRP has_VBZ been_VBN widely_RB thought_VBN ,_, but_CC
          never_RB been_VBN proven_VBN that_IN the_DT specific_JJ tyrosine_NN kinase_NN
          inhibitors_NNS such_JJ as_IN Gleevec_NNP can_MD be_VB used_VBN as_IN adjuvant_NN
          therapy_NN in_IN combination_NN with_IN conventional_JJ chemotherapy_NN ,_,
          because_IN the_DT limited_JJ clinical_JJ trial_NN data_NNS suggests_VBZ only_RB a_DT
          marginal_JJ benefits_NNS using_VBG this_DT kind_NN of_IN drug_NN to_TO treat_VB the_DT
          cancer_NN alone_RB (_( John_NNP Rogers_NNP ,_, WVU_NNP Cancer_NNP center_NN ,_, ECOG_NNP trial_NN
          member_NN ,_, personal_JJ communication_NN )_) ._. Current_JJ study_NN results_NNS
          suggests_VBZ that_IN Gleevec_NNP can_MD potentiate_NN the_DT cisplatin_NN effect_NN
          on_IN A_DT 549_CD lung_NN cancer_NN cells_NNS ,_, and_CC these_DT findings_NNS provide_VBP
          important_JJ in_IN vitro_NN data_NNS for_IN further_JJ testing_VBG the_DT
          possibility_NN of_IN using_VBG Gleevec_NNP as_IN adjuvant_NN therapy_NN for_IN
          clinical_JJ lung_NN cancer_NN patients_NNS ._.
        
      
      
        Methods_NNP
        
          Cell_NNP culture_NN and_CC drug_NN testing_NN
          Lung_NNP cancer_NN cell_NN line_NN A_DT 549_CD cells_NNS were_VBD cultured_JJ in_IN DMEM_NNP
          with_IN 5_CD %_NN fetal_JJ calf_NN serum_NN as_IN described_VBN ._. The_DT cells_NNS are_VBP
          seeded_VBN in_IN 96_CD -_: well_RB plate_NN at_IN the_DT cell_NN density_NN of_IN 2_CD -_: 4_CD ×_NN 10_CD
          4_CD per_IN well_RB as_IN indicated_VBN ,_, and_CC the_DT tumor_NN cells_NNS were_VBD cultured_JJ
          in_IN the_DT medium_NN containing_VBG serum_NN ._. Cisplatin_NNP was_VBD purchased_VBN
          from_IN Sigma_NNP Chemicals_NNPS (_( St_NNP ._. Louis_NNP ,_, MO_NNP )_) ,_, and_CC dissolved_VBN in_IN
          water_NN at_IN the_DT concentration_NN of_IN 32_CD mM_NN ._. The_DT Gleevec_NNP
          (_( Novartis_NNP Pharmaceuticals_NNP ._. Inc_NNP ._. ,_, NJ_NNP )_) was_VBD purchased_VBN from_IN
          the_DT outpatient_NN pharmacy_NN at_IN West_NNP Virginia_NNP University_NNP and_CC
          dissolved_VBN in_IN water_NN at_IN the_DT concentration_NN of_IN 1_CD mM_NN ._. The_DT
          experimental_JJ procedure_NN for_IN the_DT cisplatin_NN and_CC Gleevec_NNP
          treatment_NN was_VBD the_DT following_VBG :_: The_DT A_DT 549_CD cells_NNS and_CC human_JJ 293_CD
          cells_NNS were_VBD plated_JJ into_IN the_DT 96_CD well_RB plates_NNS at_IN the_DT cell_NN
          density_NN indicated_VBD and_CC the_DT cells_NNS were_VBD allowed_VBN to_TO attach_VB
          overnight_JJ ._. The_DT attached_VBN cells_NNS in_IN the_DT plates_NNS were_VBD washed_VBN
          once_RB with_IN PBS_NNP and_CC replaced_VBN with_IN fresh_JJ medium_NN containing_VBG
          various_JJ concentrations_NNS of_IN drugs_NNS indicated_VBD ._. The_DT MTT_NNP assays_NNS
          were_VBD performed_VBN after_IN 48_CD hours_NNS of_IN continuous_JJ incubation_NN
          with_IN medium_NN containing_VBG the_DT drugs_NNS ._. The_DT values_NNS shown_VBN in_IN the_DT
          figures_NNS are_VBP mean_VB readings_NNS from_IN five_CD wells_NNS in_IN each_DT
          experiments_NNS and_CC representative_NN of_IN three_CD independent_JJ
          experiments_NNS ._.
        
        
          MTT_NNP assays_NNS
          We_PRP have_VBP performed_VBN a_DT series_NN of_IN MTT_NNP assays_NNS to_TO determine_VB
          the_DT effects_NNS of_IN the_DT anti-tumor_JJ drug_NN STI_NNP 571_CD on_IN the_DT number_NN
          of_IN A_DT 540_CD lung_NN cancer_NN cells_NNS and_CC human_JJ 293_CD kidney_NN cells_NNS ._. The_DT
          assay_NN is_VBZ based_VBN upon_IN the_DT cleavage_NN of_IN the_DT yellow_JJ
          tetrazolium_NN salt_NN MTT_NNP
          [_NN 3_CD -_: (_( 4_CD ,_, 5_CD -_: dimethylthiazol-_NN 2_CD -_: yl_NN )_) -_: 2_CD ,_, 5_CD -_: diphenyl_NN tetrazolium_NN
          bromide_NN ]_NN to_TO purple_JJ formazan_NN crystals_NNS by_IN metabolically_RB
          active_JJ cells_NNS [_NN 15_CD ]_NN ._. The_DT tested_VBN concentration_NN of_IN Gleevec_NNP
          ranged_VBD from_IN 0_CD ._. 5_CD to_TO 8_CD μM_NN ._. The_DT tumor_NN cells_NNS were_VBD seeded_VBN into_IN
          96_CD -_: well_RB culture_NN plate_NN ,_, and_CC maintained_VBD for_IN culture_NN for_IN 24_CD
          hours_NNS before_IN the_DT first_JJ compound_NN was_VBD added_VBN to_TO the_DT medium_NN ._.
          The_DT cultured_JJ cells_NNS were_VBD incubated_JJ in_IN a_DT medium_NN containing_VBG
          5_CD %_NN serum_NN and_CC treated_VBN with_IN Gleevec_NNP for_IN 48_CD hours_NNS ._. After_IN
          treatment_NN ,_, 10_CD μl_NN of_IN MTT_NNP labeling_VBG reagent_NN were_VBD added_VBN to_TO
          each_DT well_RB and_CC plates_NNS were_VBD incubated_JJ at_IN 37_CD °_NN C_NNP for_IN 4_CD h_NN ._.
          Following_VBG MTT_NNP incubation_NN ,_, the_DT cultures_NNS were_VBD solublized_JJ
          and_CC the_DT spectrophotometric_JJ absorbance_NN of_IN the_DT samples_NNS was_VBD
          detected_VBN by_IN using_VBG a_DT microtiter_NN plate_NN reader_NN ._. The_DT
          wavelength_NN to_TO measure_VB absorbance_NN of_IN formazan_NN product_NN is_VBZ
          570_CD nm_NN ,_, with_IN a_DT reference_NN wavelength_NN of_IN 750_CD nm_NN ._.
        
        
          Immunofluorescent_NNP staining_VBG of_IN the_DT cultured_JJ
          cells_NNS
          The_DT A_DT 549_CD cells_NNS were_VBD cultured_JJ as_IN described_VBN on_IN the_DT
          coverslips_NNS ,_, and_CC fixed_VBD with_IN 3_CD ._. 7_CD %_NN paraformaldehyde_NN for_IN 10_CD
          minutes_NNS at_IN room_NN temperature_NN ._. The_DT fixed_VBN cells_NNS were_VBD
          permeablized_JJ with_IN 3_CD %_NN Triton_NNP X-_NNP 100_CD in_IN PBS_NNP and_CC directly_RB
          used_VBN for_IN immunofluorescent_NN and_CC immunocytochemical_JJ
          stainings_NNS ._. The_DT primary_JJ anti-_NN PDGFR-α_NNP antibody_NN was_VBD
          purchased_VBN from_IN Santa_NNP Cruz_NNP Biotechnologies_NNP Inc_NNP (_( Santa_NNP
          Cruz_NNP ,_, CA_NNP )_) ._. The_DT secondary_JJ antibody_NN for_IN immunofluorescent_NN
          labeling_VBG was_VBD from_IN Molecular_NNP Probe_NNP Inc_NNP ._. (_( Portland_NNP ,_,
          OR_NNP )_) ._.
        
        
          Lung_NNP tumor_NN tissue_NN microarrays_NNS and_CC
          immunohistochemical_JJ staining_VBG
          The_DT high-density_JJ lung_NN cancer_NN tissue_NN microarray_NN slides_NNS
          were_VBD made_VBN in_IN Clinomics_NNP Bisciences_NNP Inc_NNP ._. MA_NNP ,_, and_CC was_VBD used_VBN
          for_IN immunohistochemical_JJ staining_VBG for_IN PDGFR-a_NNP ._. Briefly_NNP ,_,
          the_DT tissue_NN microarray_NN slides_NNS were_VBD sectioned_JJ at_IN 5_CD micron_NN
          in_IN thickness_NN and_CC heated_VBN to_TO 65_CD °_NN C_NNP for_IN 10_CD minutes_NNS to_TO
          de-parafinize_JJ the_DT tissues_NNS ._. The_DT slides_NNS were_VBD washed_VBN three_CD
          times_NNS in_IN xylene_NN ,_, then_RB dehydrated_JJ and_CC rehydrated_JJ in_IN 100_CD %_NN ,_,
          95_CD %_NN and_CC 70_CD %_NN ethanol_NN ._. The_DT tissue_NN sections_NNS were_VBD finally_RB
          washed_VBN with_IN PBS_NNP once_RB before_IN going_VBG through_IN the_DT antigen_NN
          retrieval_NN process_NN ._. The_DT antigen_NN retrieval_NN was_VBD performed_VBN
          using_VBG citrate_NN buffer_NN (_( pH_NN 7_CD ._. 4_LS )_) at_IN 90_CD °_NN C_NNP for_IN 30_CD minutes_NNS ._. The_DT
          immunohistochemical_JJ staining_VBG was_VBD performed_VBN using_VBG Ventana_NNP
          Bench_NNP Mark_NNP II_NNP automated_VBN staining_VBG device_NN following_VBG the_DT
          manufacturer_NN 's_POS instruction_NN (_( Ventana_NNP Medical_NNP Inc_NNP ._. Tucson_NNP ,_,
          AZ_NNP )_) ._. The_DT primary_JJ PDGFR-α_NNP antibody_NN was_VBD from_IN Santa_NNP Cruz_NNP
          Biotechnologies_NNP Inc_NNP (_( Santa_NNP Cruz_NNP ,_, CA_NNP )_) ._. The_DT tumor_NN section_NN
          slides_NNS and_CC the_DT immunostaining_VBG patterns_NNS were_VBD reviewed_VBN by_IN
          two_CD independent_JJ practicing_NN surgical_JJ pathologists_NNS ,_, and_CC the_DT
          signal_NN intensities_NNS were_VBD scored_VBN at_IN 1_CD +_NN ,_, 2_CD +_NN and_CC 3_CD +_NN ._. The_DT
          staining_VBG characteristics_NNS of_IN all_DT tumors_NNS were_VBD summarized_VBD in_IN
          Table_NNP I_PRP ._.
        
        
          Western_NNP blotting_VBG
          The_DT A_DT 549_CD cells_NNS were_VBD maintained_VBN in_IN the_DT culture_NN
          condition_NN as_IN described_VBN above_IN ._. Western_NNP blotting_VBG analyses_NNS
          of_IN PDGF_NNP receptors_NNS were_VBD performed_VBN using_VBG a_DT previously_RB
          described_VBN method_NN [_NN 16_CD ]_NN ._. Briefly_NNP ,_, the_DT tumor_NN cells_NNS were_VBD
          treated_VBN with_IN Gleevec_NNP at_IN the_DT various_JJ concentrations_NNS for_IN 6_CD
          hours_NNS ._. The_DT whole_JJ cell_NN extracts_NNS were_VBD prepared_VBN and_CC used_VBN for_IN
          Western_JJ blot_NN with_IN anti-_NN PDGF_NNP receptor_NN α_NN using_VBG RIPA_NNP buffer_NN
          containing_VBG SDS_NNP ._. The_DT whole_JJ cell_NN extracts_NNS were_VBD separated_JJ on_IN
          the_DT 7_CD ._. 5_CD %_NN SDS_NNP PAGE_NNP and_CC transferred_VBN onto_IN nitrocellulose_NN
          membrane_NN by_IN electroblotting_VBG ._. The_DT primary_JJ antibody_NN was_VBD
          incubated_JJ in_IN the_DT 5_CD %_NN non-fat_JJ milk_NN with_IN the_DT proteins_NNS on_IN the_DT
          membrane_NN overnight_JJ at_IN 4_CD °_NN C_NNP ,_, and_CC the_DT protein_NN of_IN interest_NN
          was_VBD visualized_JJ by_IN the_DT enhanced_JJ chemiluminescent_NN method_NN
          (_( ECL_NNP )_) ._. The_DT anti-_NN PDGF_NNP receptor_NN α_NN antibody_NN was_VBD used_VBN at_IN
          1_CD :_: 500_CD (_( Santa_NNP Cruz_NNP Biotechnologies_NNP Inc_NNP ._. CA_NNP )_) ._.
        
      
      
        Author_NN 's_POS contributions_NNS
        PZ_NNP designed_VBD ,_, organized_VBD the_DT whole_JJ study_NN and_CC analyzed_VBD all_PDT
        the_DT data_NN ._. WG_NNP performed_VBD a_DT majority_NN of_IN the_DT experiments_NNS in_IN the_DT
        study_NN ._. ST_NNP provided_VBD micro-array_JJ slides_NNS for_IN lung_NN cancers_NNS ,_, and_CC
        discussed_VBD extensively_RB regarding_VBG the_DT design_NN and_CC execution_NN of_IN
        the_DT study_NN ._. BSD_NNP reviewed_VBD the_DT patient_NN 's_POS tumor_NN specimens_NNS ._. All_DT
        authors_NNS read_VBP and_CC approved_VBD the_DT final_JJ manuscript_NN ._.
      
    
  
